Cargando…
Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma
BACKGROUND: Gliosarcoma is a rare variant of glioblastoma (GBM) that exhibits frequent mutations in TP53 and can develop in a secondary fashion after chemoradiation of a primary GBM. Whether temozolomide (TMZ)-induced mutagenesis of the TP53 DNA-binding domain (DBD) can drive the pathogenesis of gli...
Autores principales: | Pain, Margaret, Wang, Huaien, Lee, Eunjee, Strahl, Maya, Hamou, Wissam, Sebra, Robert, Zhu, Jun, Yong, Raymund L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788663/ https://www.ncbi.nlm.nih.gov/pubmed/29416795 http://dx.doi.org/10.18632/oncotarget.23517 |
Ejemplares similares
-
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients
por: Cho, Sung-Yup, et al.
Publicado: (2017) -
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022) -
Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma
por: Kiang, Karrie Mei-Yee, et al.
Publicado: (2021) -
Metastatic secondary gliosarcoma: patient series
por: Baisiwala, Shivani, et al.
Publicado: (2023) -
Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)